An interventional study of Sedation protocol in Intensive Care (ICU), Respiratory Distress Syndrome (RDS) and Sedation and Analgesia, sponsored by Guy's and St Thomas' NHS Foundation Trust. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.
Sponsored by Guy's and St Thomas' NHS Foundation Trust · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Respiratory Distress Syndrome with a site in United Kingdom — 10 open to participants now, 13 under way, 3 of them phase 3. Respiratory Distress Syndrome · United Kingdom.
Among the 47 studies in Respiratory Distress Syndrome with a site in United Kingdom, this one is the 17th largest by planned enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2026, is one of 10 with no phase, reaches primary completion later than 6 of the 12 other live ones, and was the 46th registered.
1,388 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →10 of the 47 studies in Respiratory Distress Syndrome with a site in United Kingdom are open now. Recruiting first, the newest first:
Guy's and St Thomas' NHS Foundation Trust · Sites in United Kingdom
Ages 18–100
Aerogen Pharma Limited · Sites in United Kingdom, United States, Canada
Ages 1 hrs–24 hrs
BioAegis Therapeutics Inc. · Sites in United Kingdom, United States, Belgium and 10 more countries
Ages 18+
King's College Hospital NHS Trust · Sites in United Kingdom
Ages 34 wk–38 wk
Guy's and St Thomas' NHS Foundation Trust · Sites in United Kingdom
Ages 17+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 8 · Phase 4 2
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 60 across 823 interventional studies indexed under Respiratory Distress Syndrome.
Median enrollment 90 across the 31 interventional studies, 132 across the 15 observational. Of the 27 that completed or were terminated, 6 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 47 have an industry lead sponsor. The 10 most frequent:
Guy's and St Thomas' NHS Foundation Trust is the lead sponsor of 295 studies on the registry; 80 are open to participants now.
Guy's and St Thomas' NHS Foundation Trust has 5 studies filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
8 of the studies in Respiratory Distress Syndrome with a site in United Kingdom that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06776783Phase 3Aerogen Pharma LimitedSafety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome | 2027-05 |
| NCT06014138Phase 3Guy's and St Thomas' NHS Foundation TrustVolatile Sedation for Patients With the Acute Respiratory Distress Syndrome | 2027-07-31 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05388708University of MichiganARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND) | 2027-06-30 |
| NCT07580781Guy's and St Thomas' NHS Foundation TrustFeasibility of Protocolised Analgosedation in ECMO | 2027-08-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 47 studies in Respiratory Distress Syndrome with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sedation (painkillers and sedative drugs) treats pain, reduces suffering, and helps patients in the intensive care unit (ICU) receiving extracorporeal membrane oxygenation (ECMO) remain comfortable. ECMO is a life support machine that provides oxygen and removes waste gases (carbon dioxide) in very sick patients with severe heart or lung failure. About 300-400 patients per year receive ECMO in the UK. These patients are younger and generally more healthy compared to other critically ill patients. However patients that survive ECMO have long-term health problems. These include anxiety, memory problems, withdrawal from medicines, and mobility issues. These problems issues could all be related to the type and amount of sedation given.
A sedation protocol is a way of guiding healthcare professionals how much sedation is given to patients in ICU. Too much sedation can cause confusion, hallucinations, excessive sleepiness, and longer time in hospital. Too little sedation can cause pain, distress, and also a longer time in hospital. Using a sedation protocol in non-ECMO patients has been shown to reduce these complications.
However, there are no protocols for giving sedation to ECMO patients in research papers. Investigators know healthcare staff find it difficult to manage sedation, and higher amounts of sedation is given to ECMO patients.
Aims:
To see whether it is possible to run a trial that compares using a sedation protocol against usual care.
Design/methods:
Thirty to 60 ECMO patients will be chosen and will be put into one of two groups. One group will receive usual care, and the other will receive care using the sedation protocol. The investigators will collect information from both groups to find out if the study design works and how many patients agree to take part.
Patient and public involvement/engagement:
The investigators received feedback from patients and family member participants which helped to design this proposal, the lay summary and what to measure in a trial. They will advise how the investigators should review study findings, and support sharing of results to the public.
Impact/dissemination:
The investigators will share findings through social media, patient charities, research papers and conferences.
Research questions
STUDY AIM AND OBJECTIVES Overall aim and purpose • The overall aim is to test the feasibility of a cRCT of a co-designed analgosedation protocol for use with adult extracorporeal membrane oxygenation (ECMO) patients.
Objectives
Overall objective
Feasibility objectives
Exploratory clinical objectives include
STUDY DESIGN
The investigators will conduct a feasibility cRCT in two tertiary adult ECMO centres within Guy's \& St Thomas' NHS Foundation Trust (St Thomas' Hospital (cluster 1) and Royal Brompton Hospital (cluster 2)). The investigators have chosen a cRCT study design to reduce intervention contamination by healthcare professional participants delivering care in the intervention or control arms. This is important to ensure all patients within the same cluster receive the same treatment.
Study procedures
Control arm: Will comprise the standard of care for delivery of analgosedation and all other medical treatment while in the ICU. Standard of care includes use of pain (Critical-Care Pain Observation Tool - CPOT), and sedation (Richmond Agitation and Sedation Scale - RASS) scores to assess pain and sedation levels, and the use of opioids and sedatives to keep patients comfortable and pain-free with drug type and dosing selected by the ICU clinical team. One cluster (ICU) will be randomly assigned to this arm.
Intervention arm: Will comprise the use of the previously co-designed analgosedation protocol. The analgosedation protocol will focus on setting a daily target for pain using the CPOT score, and sedation using the RASS score. The protocol will include recommended opioid and sedative medicines and their dose ranges, guidance on titration of opioid and sedative doses based on pain and sedation scores, daily interruption of sedation, use of non-pharmacological approaches to keep patients calm and to promote sleep, and methods of weaning opioids and sedatives. Patients will also be assessed daily for delirium using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). All other treatments will be as per standard care and at the discretion of the treating clinical team. The sedation protocol will be used for up to 10 days after commencement of ECMO. One cluster (ICU) will be randomly assigned to this arm.
Randomisation and blinding
The ECMO unit will be the unit of randomisation, with patients allocated to treatment or control according to their assigned cluster. Participants will be included if they meet the inclusion criteria. Randomisation will be performed via the Sealed Envelope online randomisation module following ethics approval to provide enough time to organise staff training on the use of the protocol. Each cluster will be informed ahead of time as to which arm they will be allocated to for the purposes of training on the protocol. Given the nature of the intervention, neither the treating clinicians, patients, nor data collectors can be blinded. However, exploratory outcome measures are objective and documented in the patient's medical record.
Staff training on the use of the protocol
Healthcare professionals (doctors, nurses and pharmacists) will receive training from the research team on the use of the protocol prior to the study launching and during trial recruitment in the centre allocated to the intervention arm. The investigators will provide training (in-person and virtually) on elements of the trial protocol, including analgosedation dose titration, targeted Richmond Agitation and Sedation Scale (RASS) scores, and the duration of protocol use. The investigators will also provide refresher training to staff in both arms of the study on the use of CPOT, RASS, and CAM-ICU assessments. A training log will be used to determine who has been trained and the date of training.
Success criteria
The investigators will assess the following criteria to inform progression to seeking funding for a future cRCT.
Progression criteria
The investigators will use a traffic light system to guide progression criteria as recommended in best practice guidelines.
Green: Progress to apply for trial funding, with review of screening logs and protocol revision to address any barriers to recruitment and delivery of the intervention.
Amber: Consider progression to apply for trial funding with consultation with key stakeholders, review of screening logs, and protocol revision to address any barriers to recruitment, delivery of the intervention and harness facilitators.
Red: Unable to progress to trial funding application.
Assessment of protocol adherence
The investigators will assess protocol adherence daily using a fidelity checklist. Adherence to the protocol will be deemed good if 70% of daily fidelity checklist items have been met over the study period.
Assessment of acceptability of the protocol
Staff participants will complete the validated Acceptability of Intervention Measure (AIM)/Feasibility of Intervention Measure (FIM) questionnaires and will be offered the opportunity to participate in an interview. The questionnaire will include questions including whether the analgosedation protocol meets staff approval and is appealing for ECMO patients, and if it is liked and welcomed for use in clinical practice. The AIM/FIM questionnaire will be administered daily to staff, who have used the protocol, before they go home after their day or night shift. The investigators will use codes to track if staff have answered the AIM questionnaire more than once during the study period. The analgosedation protocol will be deemed acceptable if all participants rated the acceptability questions as a mark of 4 (agree) or 5 (completely agree) in 70% of cases across all completed questionnaires.
Fidelity
The investigators will use the Theoretical Domains Framework (TDF) to guide both the measurement of fidelity and to understand factors affecting trial delivery. The progression criteria for protocol adherence are based on at least a 70% fidelity rate in line with a previous study.
Data to be collected
Feasibility and fidelity trial data
The direct care team will enter de-identified data on to the electronic case report form (e-CRF). The investigators will develop an e-CRF to collect de-identified patient demographic characteristics, analgosedation management and patient outcomes in the intervention and control arms. The investigators will develop an additional e-CRF to allow the collection of feasibility data (assessment of protocol adherence). The research team will enter de-identified data to the electronic data capture system (REDCap). This is to ensure participant confidentiality. The investigators will ensure a delegation log is completed.
Data collected will include baseline characteristics and severity scores (age, gender, height, weight, body mass index, worst documented PaO2/FiO2 (P/F) ratio prior to ECMO cannulation, APACHE II scores, admission SOFA scores, admission C-reactive protein, pregnancy or postpartum, ECMO modality, primary reason for ECMO, admission type, past medical history), and exploratory clinical objectives from the patient's medical notes. The research team will record all patients who were enrolled into the study using a Site Master Log sheet and Screening Log, and record any concerns relating to the intervention. The investigators will collect sedation data up to 10 days for the intervention and control arms.
The investigators will collect data on intervention fidelity at the site using the sedation protocol using the fidelity checklist.
The investigators will conduct semi-structured interviews online via Microsoft Teams with staff participants to explore their perceptions of barriers and facilitators to use of the co-designed sedation protocol and their views on its acceptability during the feasibility trial. The investigators will use a interview guide and a questionnaire, which will be based on the TDF and the AIM/FIM Questionnaire. The investigators will use purposive sampling (based on years of ICU experience and the number of patient participants they have managed using the protocol) to interview doctors, nurses, and pharmacists involved in protocol delivery. The investigators will collect basic demographic characteristics, professional role, years of ICU experience. All interviews will be digitally recorded and transcribed by a professional transcription company.
Data analysis
Quantitative analysis
Fidelity analysis
The investigators will sum the scores of the daily checklist to a maximum score of 8 (if an item on the checklist is ticked yes, a score of 1 is added). The investigators will average the scores of all the daily checklists completed per patient during study enrolment. Protocol adherence will be defined as at least 70% of the daily checklist score.
Acceptability questionnaire analysis
The investigators will review all completed AIM/FIM questionnaires and if at least 70% of responses are recorded as 4 (agree) or 5 (completely agree), acceptability will be achieved.
Exploratory patient outcomes
The investigators will calculate the mean (standard deviation) and median (interquartile range) of duration of mechanical ventilation, occurrence and duration of delirium, duration of ECMO, daily (24-hour period) dose of each analgosedation drug, ICU and hospital length of stay, and ICU and hospital mortality. The investigators will also calculate counts (%) for occurrence of delirium, accidental removal of the endotracheal tube, accidental removal of other tubes and invasive lines, and use of physical restraints. The investigators will convert all opioids (enteral and intravenous) to morphine dose equivalents; benzodiazepines (enteral and intravenous) into midazolam dose equivalents using opioid and benzodiazepine conversion tables (47,48). The investigators will calculate daily doses by dividing the sum of all analgosedation doses received during the data collection period by the number of days of collected data. Data will be analysed using R Studio.
Qualitative analysis
To analyse data on barriers, facilitators and acceptability, the investigators will use the Framework Method informed by the AIM/FIM Questionnaire and Theoretical Domains Framework (TDF). The investigators will dual-code transcripts coding data within the domains of the TFA and the TDF. The investigators will group and mark codes from the transcripts with one or more short descriptors to organise the raw data. The codes will then be grouped, summarised and categorised within the framework. The investigators will use NVIVO to support the coding and the analysis of the qualitative data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The analgosedation protocol will focus on setting a daily target for pain using the CPOT score, and sedation using the RASS score. The protocol will include recommended opioid and sedative medicines and their dose ranges, guidance on titration of opioid and sedative doses based on pain and sedation scores, daily interruption of sedation, use of non-pharmacological approaches to keep patients calm and to promote sleep, and methods of weaning opioids and sedatives. Patients will also be assessed daily for delirium using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). All other treatments will be as per standard care and at the discretion of the treating clinical team. The sedation protocol will be used for up to 10 days after commencement of ECMO. One cluster (ICU) will be randomly assigned to this arm.
Other: Sedation protocol
Will comprise the standard of care for delivery of analgosedation and all other medical treatment while in the ICU. Standard of care includes use of pain (Critical-Care Pain Observation Tool - CPOT), and sedation (Richmond Agitation and Sedation Scale - RASS) scores to assess pain and sedation levels, and the use of opioids and sedatives to keep patients comfortable and pain-free with drug type and dosing selected by the ICU clinical team. One cluster (ICU) will be randomly assigned to this arm.
Will comprise the use of the previously co-designed analgosedation protocol. The analgosedation protocol will focus on setting a daily target for pain using the CPOT score, and sedation using the RASS score. The protocol will include recommended opioid and sedative medicines and their dose ranges, guidance on titration of opioid and sedative doses based on pain and sedation scores, daily interruption of sedation, use of non-pharmacological approaches to keep patients calm and to promote sleep, and methods of weaning opioids and sedatives. Patients will also be assessed daily for delirium using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). All other treatments will be as per standard care and at the discretion of the treating clinical team. The sedation protocol will be used for up to 10 days after commencement of ECMO. One cluster (ICU) will be randomly assigned to this arm.
Also known as: Analgosedation protocol
Feasibility of protocolised sedation
Ability to; 1. Assess fidelity of intervention delivery (adherence to the study protocol) 2. Establish barriers and facilitators to trial conduct and intervention delivery 3. Assess the feasibility of data collection methods 4. Assess the acceptability of the co-designed analgosedation protocol from the perspectives of nursing, medical, and pharmacy staff using it.
Time frame: From date of randomisation to the end of treatment at 10 days, assessed up to 10 days
Duration of mechanical ventilation
Defined as time from randomisation until first successful unassisted breathing (no inspiratory support for 48hrs or ECMO) or death or hospital discharge (at recruiting site). Mean or median time in hours.
Time frame: Defined as date of randomisation until first successful unassisted breathing (no inspiratory support for 48hrs or ECMO) or death or hospital discharge (at recruiting site), assessed up to 30 days. Censor at hospital discharge in recruiting centre.
Occurrence and duration of delirium
Occurrence and duration of delirium
Time frame: From date of randomisation to 10 days or death or transfer if occurs first, assessed up to 10 days.
Duration of ECMO treatment
Number of days of ECMO treatment from start date to finish date of ECMO
Time frame: From date of randomisation to ECMO decannulation, assessed up 30 days.
Daily morphine equivalent doses
Total doses of enteral and intravenous opioids
Time frame: From date of randomisation to 10 days or death/transfer if occurs first, assessed up to 10 days.
Daily midazolam equivalent doses
Total enteral and intravenous benzodiazepine doses
Time frame: From date of randomisation to 10 days or death/transfer if occurs first, assessed up to 10 days.
Daily propofol doses
Total propofol doses
Time frame: From date of randomisation to 10 days or death/transfer if if occurs first, assessed up to 10 days.
ICU length of stay
Duration of stay in ICU (days) in recruiting centre
Time frame: From date of randomisation to end of stay in ICU in recruiting centre, assessed up to 30 days.
Hospital length of stay
Duration of stay in hospital (days) in recruiting centre
Time frame: From date of randomisation to end of stay in hospital in recruiting centre, assessed up to 30 days.
ICU mortality
Death in ICU in recruiting centre
Time frame: From date of randomisation to death in ICU in recruiting centre, assessed up to 30 days.
Hospital mortality
Death in hospital of recruiting centre
Time frame: From date of randomisation to death in hospital in recruiting centre, assessed up to 30 days.
Accidental removal of the endotracheal tube
Removal of endotracheal tube by patient during protocolised sedation
Time frame: From date of randomisation to 10 days or death or transfer if occurs first, assessed up to 10 days.
Accidental removal of other tubes and invasive lines
Removal of other tubes and invasive lines by patient during protocolised sedation
Time frame: From date of randomisation to 10 days or death or transfer if occurs first, assessed up to 10 days.
Use of physical restraints
Use of physical restraints during protocolised sedation
Time frame: From randomisation to 10 days or death or transfer if occurs first, assessed up to 10 days.
Plan to share: Yes — The King's Open Research Data System (KORDS) at King's College London will be used as a data repository, which will provide long-term storage and access for anonymised data and study protocol at project-end and to support publications. KORDS uses the Figshare data repository platform, providing a simple, self-deposit way for researchers to upload and share their data, and a publicly accessible showcase of datasets from King's research. It supports Open Research, enabling researchers to make datasets discoverable, accessible and citeable. All datasets have a DOI and a structured metadata record so that they can be shared and cited when re-used. Depositing meets the policy requirements of funders for data retention and sharing, and the requirements of many publishers for access to datasets supporting publications.
Supporting information: Study protocol
Time frame: The data will be made available following publication of research findings in peer-reviewed manuscripts and presentation at international conferences.
Access criteria: Institution access will be needed to access any data. This includes permission to access the specific university and hospital servers. Potential users will require tools including Microsoft Excel and Microsoft Word to access and use the data, which are widely adopted in many institutions and sustainable. The data will be shared via the University repository KORDS but it will not be openly accessible. Requests for access to the data will be handled directly by the research team in line with local policies.
Data sharing details ↗ · www.kcl.ac.uk
Start is estimated for Sep 2026; primary completion for Aug 2027, 11 months later.
Of 266 non-industry interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 11 months is below that.
Counting every sponsor, half of 273 studies reached it within 24 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →
Guy's and St Thomas' NHS Foundation Trust →